AzTrials
AzTrials

DIFFUSE LARGE B-CELL LYMPHOMAPhase 2LATE-R-GEL-23NCT07254754

Study to Evaluate the Efficacy of Axicabtagene Ciloleucel in Patients With Late Relapse of Diffuse Large B-Cell Lymphoma

A Phase 2 study testing Axicabtagene Ciloleucel in people with DIFFUSE LARGE B-CELL LYMPHOMA, run by Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea at 15 sites in Spain.

Recruiting

Looking for participants now. Contact the study team or a site below to ask about taking part.

Sites and contacts
Official record
Search all trials

Trial summary

Single-arm, open-label, multicenter, phase II trial aiming to include approximately 45 patients over 24 months. Patients will receive axicabtagene ciloleucel infusion and will be followed up to 5 years. The total duration of the study is therefore of 7 years. Read more about this study

Who is it for?
Ages 18 years and older
Conditions the study is for
DIFFUSE LARGE B-CELL LYMPHOMA
What is being tested?
Axicabtagene Ciloleucel
Type of treatment
Injection or infusion
Could I receive a placebo?
No, everyone receives an active treatment
How many people
45 participants
Where
15 sitesSpain
Study dates
20 Nov 2024to 31 Dec 2031
Phase
Phase 2
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Signed written Informed Consent Form
  • Age > 18 years
  • Patient who understands and speaks one of the country official languages
  • Histologically proven relapsed or refractory aggressive B-cell non-Hodgkin lymphoma (B-NHL) of the following histology at relapse: diffuse large B-cell lymphoma (DLBCL), high-grade B-cell lymphoma (HGBL) and follicular lymphoma Grade 3B per WHO 2016 classification. Indolent B-NHL who transformed into aggressive B-NHL and were previously treated with R-CHOP-like after transformation are eligible. Primary mediastinal B-cell lymphoma are not eligible.
  • Positron-emission tomography (PET)-positive disease
  • Patients must have received adequate first-line therapy including at a minimum:
Show all 24Show fewer
  • An anti-CD20 monoclonal antibody (rituximab or obinutuzumab), and
  • CHOP or CHOP-like chemotherapy Note: CHOP-like chemotherapy corresponds to ACVBP, EPOCH, or COPADEM. Dose-reduced CHOP (i.e., miniCHOP) is excluded except for dose-reductions of vincristine due to peripheral neuropathy. Patients who have received additional drugs in combination with CHOP or CHOP-like regimen are eligible.
  • Relapsed disease after first line chemo immunotherapy (full dose of R-CHOP or R-CHOP-like regimen), documented by PET-scan and biopsy:
  • Relapsed disease defined as complete remission to first-line therapy followed by biopsy-proven disease relapse after 12 months and up to 5 years from end of first-line therapy.
  • Patients must meet CAR-T-eligible criteria as defined by:
  • Patient deemed eligible for CAR T-cells therapy by the CAR-T physician
  • AND all the following criteria:
  • ECOG performance status of 0, 1 or 2
  • Adequate vascular access for leukapheresis procedure (either peripheral or central venous line)
  • Absolute neutrophil count (ANC) ≥ 1 x 109/L
  • Platelets ≥ 75 x 109/L
  • Absolute lymphocyte count ≥ 0.1 x 109/L
  • Creatinine clearance (CrCl) as estimated by Cockcroft Gault or MDRD ≥ 40 mL/min
  • Serum alanine aminotransferase/aspartate aminotransferase (ALT/AST) ≤ 2.5xULN
  • Total bilirubin <1.5 mg/dL, except in patients with Gilbert's syndrome
  • Cardiac ejection fraction ≥ 45%
  • Baseline oxygen saturation ≥ 92% on room air
  • Females of childbearing potential must have a negative serum or urine pregnancy test (females who have undergone surgical sterilization or who have been postmenopausal for at least 12 months are not considered to be of childbearing potential).

Who cannot join

  • Patients who received more than one prior line of systemic therapy
  • Early relapsed disease defined as complete remission to first-line therapy followed by biopsy-proven disease relapse before 12 months from end of first-line therapy.
  • Refractory disease defined as:
  • Progressive disease (PD) during first-line therapy
  • Stable disease (SD) as best response after at least 4 cycles of first-line therapy (e.g., 4 cycles of R-CHOP)
  • Partial response (PR) as best response after at least 6 cycles, and biopsy-proven residual disease
Show all 29Show fewer
  • Patients who received first line of R-CHOP or obinutuzumab-CHOP for an indolent B-NHL who relapse as transformed aggressive B-NHL after a year from the end of first-line therapy are NOT eligible.
  • Prior CD19 targeted therapy
  • Patients with cardiac atrial or cardiac ventricular lymphoma involvement
  • Requirement for urgent therapy due to tumor mass effects, such as bowel obstruction or blood vessel compression
  • Patient with clinically significant pleural effusion
  • History of another primary malignancy that has not been in remission for at least 3 years (except for nonmelanoma skin cancer or carcinoma in situ (eg, cervix, bladder, breast)). A maintenance treatment is not allowed.
  • Patients with detectable Central Nervous System (CNS) lymphoma. Patients with a history of CNS lymphoma but no active CNS disease (after systematic MRI and lumbar puncture) at the time of enrolment will be eligible.
  • Presence of CNS disorder such as dementia, autoimmune disease with CNS involvement, cerebral edema with confirmed structural defects by appropriate imaging, or seizure disorders requiring active anticonvulsive medication. History of stroke, transient ischemic attack, or posterior reversible encephalopathy syndrome (PRES) within 12 months prior to enrolment.
  • Presence of any indwelling line or drain (eg, percutaneous nephrostomy tube, indwelling Foley catheter, biliary drain, or pleural/peritoneal/pericardial catheter). Ommaya reservoirs and dedicated central venous access catheters, such as a Port-a-Cath or Hickman catheter, are permitted.
  • History of acute or chronic active hepatitis B or C infection (seropositivity). If there is a positive history of treated hepatitis B or hepatitis C (negative HBsAg and positive Anti-HBc/ positive anti-HCV), the viral load HBV DNA/ HCV RNA) must be undetectable per quantitative polymerase chain reaction (PCR) and/or nucleic acid testing
  • Positive for human immunodeficiency virus (HIV) unless taking appropriate anti-HIV medications, with an undetectable viral load by PCR and with a CD4 count > 200 cells/uL.
  • Uncontrolled systemic fungal, bacterial, viral or other infection despite appropriate antimicrobials or other treatment at the time of leukapheresis or axicabtagene ciloleucel administration
  • History of any one of the following cardiovascular conditions within the past 12 months: Class III or IV heart failure as defined by the New York Heart Association, cardiac angioplasty or stenting, myocardial infarction, unstable angina, or other clinically significant cardiac disease
  • Presence of primary immunodeficiency
  • History of any medical condition including but not limited to autoimmune disease (e.g., Crohn's disease, rheumatoid arthritis, systemic lupus) requiring systemic immunosuppression and/or systemic disease modifying agents within the last year. Endocrine conditions that require maintenance with physiologic dose steroids are allowed.
  • History of idiopathic pulmonary fibrosis, organizing pneumonia (e.g., bronchiolitis obliterans), drug-induced pneumonitis, idiopathic pneumonitis, or evidence of active pneumonitis per chest computed tomography (CT) scan at screening. History of radiation pneumonitis in the radiation field (fibrosis) is allowed.
  • History of severe immediate hypersensitivity reaction to tocilizumab or any of the agents used in this study
  • History of severe, immediate hypersensitivity reaction attributed to aminoglycosides, cyclophosphamide or fludarabine
  • Treatment with a live, attenuated vaccine within 6 weeks prior to initiation of study treatment or anticipation of need for such a vaccine during the study
  • Women of childbearing potential who are pregnant or breastfeeding because of the potentially dangerous effects of lymphodepletion chemotherapy on the fetus or infant.
  • Patients of either sex who are not willing to practice birth control from the time of consent during treatment and for at least 12 months after conditioning chemotherapy dosing or axicabtagene ciloleucel dosing, whichever is later
  • In the investigator's judgment, the patient is unlikely to complete all protocol-required study visits or procedures, including follow-up visits, or comply with the study requirements for participation
  • Adult person unable to provide informed consent because of intellectual impairment, any serious medical condition, laboratory abnormality or psychiatric illness.

Trial locations and contacts

15 sites in 1 country. Contact the study team or a site near you to ask about taking part.

Auxi Moreno contact

+34 683636850

amoreno@geltamo.com

Ana María Méndez contact

administracion@geltamo.com

15 sites in 1 country

Spain15 sites, 15 recruiting

  • Complejo Hospitalario Universitario A Coruña

    A Coruña, A Coruña, 15008

    Sandra García Doval, +34 981176668, sandragarciadoval@gmail.com

    Almudena Pérez Rodriguez, +34 981176668, almudena.perez.rodriguez@sergas.es

    Recruiting

  • Hospital Universitari Vall d'Hebron

    Barcelona, Catalonia, 08035

    Alicia Nogueroles Olivares, + 34 93 274 61 00 ext. Ext. 4976/ 26, alicianogueroles@vhio.net

    Julia Sedó, + 34 93 274 61 00 ext. Ext. 4976/2697, jsedo@vhio.net

    Recruiting

  • Hospital Clinic i Provincial de Barcelona

    Barcelona, Catalonia, 08036

    Veronica Martil, +34 913303000, MARTIL@recerca.clinic.cat

    Cecilia Vilas, CVILAS@recerca.clinic.cat

    Recruiting

  • Institut Català d'oncologia de L'Hospitalet

    L'Hospitalet de Llobregat, Catalonia, 08908

    Lydia Guillem, +34 932607750, lguillem@idibell.cat

    Mariona Guillamet, +34 932607750, mguillamet@idibell.cat

    Recruiting

  • Complejo Hospitalario Universitario de Gran Canaria Dr. Negrín

    Las Palmas de Gran Canaria, Las Palmas, 35019

    Elizabeth Alfonso Bermejo, +34 928450767, ealfonso@fciisc.es

    Julia Wiedermann, +34 928450767, jmwiedermann@fciisc.es

    Recruiting

  • Hospital General Universitario Gregorio Marañón

    Madrid, Madrid, 28007

    Soraya Oviedo, +34 914269658, soraya.oviedo.hgugm@gmail.com

    Ana García, +34 914269658, ana.garcia.hgugm@gmail.com

    Recruiting

  • Hospital Universitario 12 de Octubre

    Madrid, Madrid, 28041

    Alba Gutiérrez de la Peña, +34 917792809, albagu12oct@gmail.com

    Paula Garcés, +34 917792809, paulagarcesh12oct@gmail.com

    Recruiting

  • Hospital General Universitario Morales Meseguer

    Murcia, Murcia, 30008

    José Navarro Fernández, +34 968363969, josenafer79@gmail.com

    Josefa Gálvez Martínez, +34 968363969, josegalvez100@gmail.com

    Recruiting

  • Hospital Universitario Son Espases

    Palma de Mallorca, Balearic Islands, 7120

    Mª Teresa Ros Matheu, +34 871206268, maria.ros@ssib.es

    Silvia Roig Juan, +34 871206268, silvia.roig@ssib.es

    Recruiting

  • Clínica Universidad de Navarra

    Pamplona, Navarre, 31008

    Andoni Urrutia, +34 948 296 666 ext. Ext. 2703, aurrutia@unav.es

    Sara Morales Espinosa, +34 948 296 666 ext. Ext. 2768, smoralesesp@unav.es

    Recruiting

  • Hospital Universitario de Salamanca

    Salamanca, Castille and León, 37007

    Andrea Torices, +34 923291100 ext. 56078, atorices.ibsal@saludcastillayleon.es

    Manuel Delgado, +34 923291100 ext. 56022, mdelgadocri@saludcastillayleon.es

    Recruiting

  • Hospital Universitario Donostia

    San Sebastián, Gipuzkoa

    Nerea Castroagudín Romero, +34 943006046, NEREA.CASTROAGUDINROMERO@bio-gipuzkoa.eus

    María Aurora Barbero Martínez, +34 943006046, MARIAAURORA.BARBEROMARTINEZ@bio-gipuzkoa.eus

    Recruiting

  • Hospital Universitario Marqués de Valdecilla

    Santander, Cantabria, 39008

    Alba del Río Manzano, +34 942204078, amanzano@idival.org

    Pilar González Echezarreta, +34 942204078, mpilar.gonzaleze@scsalud.es

    Recruiting

  • Hospital Universitario Virgen del Rocío

    Seville, Sevilla, 41013

    Rocío Jiménez, +34 955013277, rociojimenezalvarez@gmail.com

    Estefanía Menéndez Pedregal, +34 955013277, estefania.menpe@gmail.com

    Recruiting

  • Hospital Clínico Universitario de Valencia

    Valencia, Valencia, 46010

    María Mercedes Bou Moreno, +34 96 197 3500 ext. Ext. 436697, mbou@incliva.es

    Carmen Hurtado Fontelles, +34 96 197 3500 ext. Ext. 436697, carmenhurtadoincliva@gmail.com

    Recruiting

Other trials in Spain

About this study

Official title: LATE-R Trial. A Phase II, Single-Arm, Open-Label, Multicenter Study to Evaluate the Efficacy of Axicabtagene Ciloleucel in Patients With Late Relapse of Diffuse Large B-Cell Lymphoma

Single-arm, open-label, multicenter, phase II trial aiming to include approximately 45 patients over 24 months. Patients will receive axicabtagene ciloleucel infusion and will be followed up to 5 years.

The total duration of the study is therefore of 7 years.

Read the detailed description

Axicabtagene Ciloleucel , an anti-CD19 chimeric antigen receptor (CAR) T-cell therapy, demonstrated a high rate of durable responses with a manageable safety profile, in patients with relapsed or refractory large B-cell lymphoma (LBCL) after two or more previous therapies. Recently, axicabtagene ciloleucel as demonstrated superior efficacy compared to standard of care (SOC) in 2nd line LBCL patients considered eligible for autologous stem-cell transplantation (ASCT) with primary refractory disease or early relapse (ZUMA-7). In this study, after a median follow-up of 24.9 months, the median event-free survival was 8.3 months in the axicabtagene ciloleucel group and 2.0 months in the standard-care group, and the 24-month event-free survival was 41% and 16%, respectively (hazard ratio, [HR] for event or death, 0.40; 95% confidence interval, 0.31 to 0.51; p<0.001). Some response occurred in 83% of the patients in the axicabtagene ciloleucel group and in 50% of those in the SOC group (with a complete response [CR] in 65% and 32% of the patients, respectively). These data led to the approval of axicabtagene ciloleucel by the American and European regulatory agencies, for patients with LBCL refractory to first-line or relapsing within the first year after completion of induction immunochemotherapy.

More recently, the open-label phase 2 ALYCANTE trial assessed the safety and efficacy of axicabtagene ciloleucel as second-line therapy in patients with primary refractory or early relapsed aggressive B-cell lymphoma who were not deemed candidates for ASCT. Treatment with axicabtagene ciloleucel resulted in high response rates (best overall response 92.5%, best CR = 80.0%) and durable remissions (median PFS, 11 months, median overall survival [OS], not reached), with an acceptable safety profile in this population of patients considered unfit for ASCT.

The above-mentioned trials included only patients who were primary refractory or had relapsed within a year of completing first-line treatment. However, no data are available on the efficacy of axicabtagene ciloleucel in second line for patients relapsing more than one year after completion of induction. Although it is generally assumed that the outcome of these patients is better than that of patients showing early failure, still the outcome is not optimal at all, with at least half of the patients dying from the lymphoma in the next months. The current proposal is aimed at studying a possible role of axicabtagene ciloleucel in this subset of cases.

Being tested
Axicabtagene Ciloleucel
Keywords
lymphoma, axicabtagene, geltamo, DIFFUSE LARGE B-CELL LYMPHOMA, DLBCL, RELAPSE
Medical subject headings
Lymphoma, Large B-Cell, Diffuse, Lymphoma, Recurrence

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Axicabtagene CiloleucelDrug

    Treatment consists of a single dose for infusion containing a dispersion for infusion of CAR-positive viable T cells in one infusion bag. The target dose is 2 × 106 CAR-positive viable T cells per kg of body weight (within a range of 1 × 106 - 2 × 106 cells/kg), with a maximum of 2 × 108 CAR-positive viable T cells for patients 100 kg and above.

Study groups in NCT07254754
Study groupRoleWhat they receive
Axicabtagene ciloleucelExperimentalTreatment consists of a single dose for infusion containing a dispersion for infusion of CAR-positive viable T cells in one infusion bag. The target dose is 2 × 106 CAR-positive viable T cells per kg of body weight (within a range of 1 × 10E6 - 2 × 10E6 cells/kg), with a maximum of 2 × 10E8 CAR-positive viable T cells for patients 100 kg and above.
Receives: Drug: Axicabtagene Ciloleucel

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Response month 3

    The Complete Metabolic Response, defined as negative findings on a PET/CT scan at month 3 after receiving axicabtagene ciloleucel infusion at day 0. The negativity of PET/CT findings will be assessed according to Lugano Classification and Deauville criteria

    Measured: Month 3

Secondary outcomes (14)

  1. Response month 3 central

    The Complete Metabolic Response defined as negative findings on a PET/CT scan at month3 after receving axicabtagene ciloleucel infusion as assessed by central imaging review of PET/CT

    Measured: Month 3

  2. Overall response rate

    The Overall response rate (ORR) defined as the percentage of patients who achieved partial metabolic response (PMR) or complete metabolic response (CMR) according to the Lugano Classification criteria at month 3 determined by both central and investigator assessments.

    Measured: Month 3

  3. Best objective response

    Best objective response rate defined as the percentage of CMR + PMR determined by the investigator assessment among all patients between month 1 and month 12 from axicabtagene ciloleucel infusion

    Measured: 1 year

  4. Best complete response rate

    Best Complete Response rate defined as the percentage of CMR determined by the investigator assessment among all patients between month 1 and month 12 from axicabtagene ciloleucel infusion

    Measured: 1 year

  5. Overall survival

    The overall survival, defined as the time from inclusion to death from any cause. Alive patients will be censored at their last follow-up date.

    Measured: Up to 5 years

  6. Progression free survival

    The Progresison Free Survival, defined as the time from axicabtagene ciloleucel infusion to the first observation of documented disease progression/relapse (based on investigator disease assessment (INV)) or death due to any cause. If a patient has not progressed or died, PFS will be censored at the time of last visit with adequate assessment

    Measured: Up to 5 years

  7. Event Free Survival

    Event-free survival (EFS), defined as the time between leukapheresis and to any event preventing axicabtagene ciloleucel infusion if axicabtagene ciloleucel is never infused, or death, disease progression, or instauration of a new lymphoma therapy for lymphoma progression after axicabtagene ciloleucel infusion. Patients without documented event at the time of analysis will be censored at the time of last visit with adequate assessment.

    Measured: Up to 5 years

  8. Duration of Response

    The Duration of Response (DOR), defined as the time from attainment of PMR or CMR to the date of first documented disease progression/relapse (based on investigator disease assessment) or death from any cause

    Measured: Up to 5 years

  9. Duration of Complete Response

    Duration of complete response (DoCR), defined as the time from achievement CMR to the date of first documented disease progression/relapse (based on investigator disease assessment) or death from any cause.

    Measured: Up to 5 years

  10. Adverse events

    Type, frequency and severity of adverse events (AEs) and serious adverse events (SAEs)

    Measured: Up to 4 weeks

  11. AESIs

    Incidence, severity and treatment of adverse events of special interest: Cytokine release syndrome (CRS), immune effector cell-associated neurotoxicity syndrome (ICANS), prolonged cytopenia and infections, hypogammaglobulinemia and emergent secondary malignancies.

    Measured: Up to 5 years

  12. Quality of Life assessed using the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)

    The EORTC QLQ-C30 is a 30-item questionnaire measuring cancer patients' physical, emotional, and social functioning. Scores range from 0 to 100. Range: 0 (worst) to 100 (best). Higher scores indicate better quality of life for functional scales and worse symptoms for symptom scales.

    Measured: Up yo 1 year

  13. Quality of Life assessed using the EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L)

    The EQ-5D-5L evaluates mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. It includes a visual analog scale (VAS) from 0 to 100. Range: 0 (worst imaginable health) to 100 (best imaginable health). Higher scores indicate better health status.

    Measured: Up to 1 year

  14. Quality of Life assessed using the EORTC Quality of Life Questionnaire for High-Grade Non-Hodgkin Lymphoma (QLQ-NHL-HG29)

    The QLQ-NHL-HG29 is a disease-specific module assessing symptoms and functioning in patients with high-grade non-Hodgkin lymphoma. Scores range from 0 to 100. Range: 0 to 100. Higher scores indicate worse symptoms or problems.

    Measured: Up to 1 year

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted28 Nov 2025
  2. Study start20 Nov 2024
  3. Primary completion31 Jan 2027 (estimated)
  4. Study completion31 Dec 2031 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrolment
45 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT07254754
Sponsor's protocol ID
LATE-R-GEL-23
Acronym
LATE-R-GEL-23
Status last verified
Nov 2025
First submitted
4 Jul 2025
Last updated
28 Nov 2025
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
Yes: Data obtained through this study may be provided to qualified researchers with academic interest in hematology diseases. All individual data collected during the trial will be available. Data shared will be coded, with no PHI included. Study protocol, statistical analysis plan, informed consent form and clinical study report will be also available. Information will be available beginning 6 months after final publication with no end date established. Approval of the request and execution of all applicable agreements are prerequisites to the sharing of data with the requesting party. Data requests can be submitted starting 6 months after article publication. Access to trial IPD can be requested by qualified researchers and will be provided following review and approval of a research and execution of a Data Sharing Agreement (DSA). For more information or to submit a request, please contact to GELTAMO though the web page: https://www.geltamo.com/contacto

Questions about this trial

What is this clinical trial studying?

A Phase 2 study testing Axicabtagene Ciloleucel in people with DIFFUSE LARGE B-CELL LYMPHOMA, run by Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea at 15 sites in Spain.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 24 inclusion and 29 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: looking for participants now, as of the sponsor's last update on 28 Nov 2025. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 15 sites in Spain. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Contact Auxi Moreno (+34 683636850, amoreno@geltamo.com), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Response month 3 (time frame: Month 3). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT07254754.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 28 Nov 2025.

AzTrials uses cookies for analytics and advertising. You can accept or reject them; the site works either way. Privacy Policy.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in